Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Primary myelofibrosis+1

Recruiting

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Primary myelofibrosis+4

Recruiting

Registered drugNo placebo

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid

Contact Research Centre

Primary myelofibrosis+1

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Navtemadlin

Contact Research Centre

Primary myelofibrosis+4

Recruiting

Registered drugNo placebo

Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Luspatercept

Contact Research Centre

Primary myelofibrosis+1

Recruiting

InvestigationalNo placebo

Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tasquinimod

Contact Research Centre

Primary myelofibrosis

Not recruiting

Registered drugNo placebo

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Luspatercept

Contact Research Centre

Primary myelofibrosis+1

Not recruiting

Registered drugNo placebo

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Danazol

Contact Research Centre

Primary myelofibrosis+1

Not recruiting

Registered drug

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Luspatercept

Contact Research Centre

Primary myelofibrosis+1

Not recruiting

Registered drugNo placebo

Study of Fedratinib and Nivolumab for Patients with Myelofibrosis Resistant to JAK-inhibitor Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fedratinib

Contact Research Centre

Primary myelofibrosis+1

Not recruiting

Registered drugNo placebo

Study of Selinexor for Patients with Previously Treated Myelofibrosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Selinexor

Contact Research Centre

Primary myelofibrosis+1

Not recruiting

Registered drugNo placebo

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Danazol

Contact Research Centre

Find therapies in clinical trials near you

11 trials match your criteria

Primary myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Primary myelofibrosis+4

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Primary myelofibrosis+1

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Primary myelofibrosis+4

Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

Primary myelofibrosis+1

Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

Primary myelofibrosis

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Primary myelofibrosis+1

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Primary myelofibrosis+1

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Primary myelofibrosis+1

Study of Fedratinib and Nivolumab for Patients with Myelofibrosis Resistant to JAK-inhibitor Treatment

Primary myelofibrosis+1

Study of Selinexor for Patients with Previously Treated Myelofibrosis

Primary myelofibrosis+1

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.